Article
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Blood advances - 22 Jul 2025
Baranwal Anmol, Langer Kimberly J, Gannamani Vedavyas, Rud Danielle, Cibich Alia, Saygin Caner, Nawas Mariam, Badar Talha, Kharfan-Dabaja Mohamed A, Ayala Ernesto, Roy Vivek, Foran James M, Murthy Hemant S, Iqbal Madiha, Palmer Jeanne, Sproat Lisa Z, Chhabra Saurabh, Khera Nandita, Hefazi Mehrdad, Mangaonkar Abhishek, Hogan William, Litzow Mark, Alkhateeb Hassan, Tefferi Ayalew, Kok Chung Hoow, Guru Murthy Guru Subramanian, Patel Anand, Bajel Ashish, Hiwase Devendra K, Shah Mithun Vinod
Abstract excerpt
ABSTRACT: Allogeneic hematopoietic stem cell transplant (alloHCT) is considered for all patients with myeloid neoplasms (MNs) harboring TP53 mutations (TP53mut). The aim of this international study across 7 transplant centers in the United States and Australia was to identify factors associated with improved post-alloHCT survival. Of 134 TP53mut MN cases who underwent alloHCT, 80% harbored complex karyotype; 94%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.